Charles B. Hicks
Abstract
Four years have passed since the licensing of the first HIV integrase inhibitor, raltegravir, and the drug has proven to be both effective and well
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Four years have passed since the licensing of the first HIV integrase inhibitor, raltegravir, and the drug has proven to be both effective and well
Key concepts: Dolutegravir, Elvitegravir, Medicine, Integrase inhibitor, Virology, Human immunodeficiency virus (HIV), Antiretroviral therapy, Viral load